The Antipsychotic Olanzapine Interacts with the Gut Microbiome to Cause Weight Gain in Mouse
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
The second-generation antipsychotic olanzapine is effective in reducing psychotic symptoms but can cause extreme weight gain in human patients. We investigated the role of the gut microbiota in this adverse drug effect using a mouse model. First, we used germ-free C57BL/6J mice to demonstrate that gut bacteria are necessary and sufficient for weight gain caused by oral delivery of olanzapine. Second, we surveyed fecal microbiota before, during, and after treatment and found that olanzapine potentiated a shift towards an "obesogenic" bacterial profile. Finally, we demonstrated that olanzapine has antimicrobial activity in vitro against resident enteric bacterial strains. These results collectively provide strong evidence for a mechanism underlying olanzapine-induced weight gain in mouse and a hypothesis for clinical translation in human patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Effect of high-fat diet (HFD) and olanzapine (OLZ) treatment on diversity of gut microbiota during crossover study. (A) Within-subject (α) diversity, quantified by Fisher's α [45]; larger values indicate greater diversity (n = 95 samples = 4 time points ×24 subjects – 1 failed sample). Panels are split by study arm (see Error! Reference source not found.) and points are colored according to diet and treatment status: on regular chow prior to initiation of HFD (regular), during treatment with placebo (HFD-placebo) or during treatment with OLZ (HFD-OLZ). Each point represents a single individual and bars indicate 95% confidence intervals about the point estimates; observations on the same subject are connected by a grey line. (B) Between-subjects (β) diversity (n = 95 samples = 4 time points ×24 subjects – 1 failed sample). Pairwise distances between samples were calculated using weighted UniFrac and visualized using non-metric multidimensional scaling along two axes, which together explain 98% of between-subjects variance. Observations on the same subject are connected by a grey line.](https://figures.cochat.ai/paper-figures/a936ae05344f4303a8dbe754682036f6/the-antipsychotic-olanzapine-interacts-with-the-gut-microbiome-to-cause-weight-figure-3.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Olanzapine administration decreased overall microbial diversity, lowered abundance of Bacteroidia, and increased abundances of Erysipelotrichia, Actinobacteria, and Gammaproteobacteria.”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [188]
In the citing paper
“a lack of significant increase of the body weight in olanzapine-treated GF mice and a rapid weight gain upon microbial colonization in this study indicate that the olanzapine-induced weight gain was dependent on the presence of gut microbiota [188].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [188]
In the citing paper
“olanzapine, which induces alterations in gut microbiome composition in rodents linked to the weight gain and other metabolic side effects that are associated with its use”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Morgan et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887 · cited 1×
“0 package [38].”
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statistics and Computing · doi:10.1007/978-0-387-21706-2 · Cited by 24,305
Naïve Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy
Wang, Q., Garrity, G. M., Tiedje, J. M., & Cole, J. R. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.00062-07 · Cited by 19,885 · cited 1×
“OTUs were assigned a taxonomic identity with the RDP classifier [37] trained on the most recent release (4 February 2011) of the Los Alamos National Laboratory’s GreenGenes taxonomic reference (gg_97_otus_4feb2011), using the scripts in the QIIME v1.”
MethodA new method for non-parametric multivariate analysis of variance
Anderson, M. J. (2001) · Austral Ecology · doi:10.1111/j.1442-9993.2001.01070.pp.x · Cited by 13,828 · cited 2×
“Between-group differences in overall microbiota composition were assessed by PERMANOVA [42] as implemented in the R package vegan (http://vegan.r-forge.r-project.org), and visualized using nonmetric multidimensional scaling as implemented in the R package MASS [43].”
MethodAn obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444 · cited 1×
“Recent studies in animal models and humans have demonstrated a causal role for the gut microbiome in obesity [19–24], which is mediated by complex interactions with host environment [25, 26], diet [21, 27] and genetics [25, 28].”
BackgroundA human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624 · cited 1×
“Bacterial concentrations can be as high as 10(11) cells/mL in the distal gut, encompassing a gene repertoire 150 times larger than that of the human host [15] with broad-ranging metabolic capacity [16, 17].”
BackgroundHuman gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785 · cited 2×
“The specific alterations in gut community composition that we attribute to olanzapine are similar to those attributed to high-fat diet [19, 21, 22, 30, 31].”
BackgroundUniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227 · cited 8×
“In the weighted UniFrac analysis (Fig.”
MethodInfluentialEffectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“Since their introduction in the 1990s, olanzapine and other atypical antipsychotics have come into widespread clinical use because they are efficacious and usually lack the extrapyramidal adverse drug reactions associated with older, ‘‘typical’’ antipsychotics like haloperidol [1, 2].”
BackgroundFastTree: Computing Large Minimum Evolution Trees with Profiles instead of a Distance Matrix
Price, M. N., Dehal, P. S., & Arkin, A. P. (2009) · Molecular Biology and Evolution · doi:10.1093/molbev/msp077 · Cited by 5,602 · cited 1×
“Consensus sequences for the OTUs were aligned using PyNAST [39] (via QIIME) guided by the aforementioned GreenGenes reference alignment, and a corresponding phylogeny inferred using FastTree [40] (via QIIME).”
Method
Cited by
Items 101–197 of 197
Can prebiotics assist in the management of cognition and weight gain in schizophrenia?
Kao, A. C.-C., Burnet, P. W. J., & Lennox, B. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.05.027 · Cited by 24
The schizophrenia and gut microbiota: A bibliometric and visual analysis
Yang, C., Lin, X., Wang, X., Liu, H., Huang, J., & Wang, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1022472 · Cited by 30
“…2017 Reza Alam 13 The Antipsychotic Olanzapine Interacts with the Gut Microbiome to Cause Weight Gain in Mouse Plos One 98 2014 Andrew P Morgan 14 Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder Journal Of Psychiatric Research 97 2018 Tanya…”
BackgroundGene expression changes following chronic antipsychotic exposure in single cells from mouse striatum
Abrantes, A., Giusti‐Rodríguez, P., Ancalade, N., Sekle, S., Basiri, M. L., Stuber, G. D., Sullivan, P. F., & Hultman, R. C. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01509-7 · Cited by 25
“Haloperidol was delivered by implanted pellets and olanzapine in food as in prior studies [37, 39] (Supplemental Methods).”
BackgroundMethodSchizophrenia and obesity: May the gut microbiota serve as a link for the pathogenesis?
Wu, H., Liu, Y., Wang, J., Chen, S., Xie, L., & Wu, X. (2023) · iMeta · doi:10.1002/imt2.99 · Cited by 26
The gut microbiome and pharmacology: a prescription for therapeutic targeting of the gut–brain axis
Leprun, P. M. B., & Clarke, G. A. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.04.007 · Cited by 25
Kowalchuk, C., Kanagasundaram, P., McIntyre, W. B., Belsham, D. D., & Hahn, M. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104400 · Cited by 24
Chait, Y. A., Mottawea, W., Tompkins, T. A., & Hammami, R. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110182 · Cited by 24
Does the gut microbiome mediate antipsychotic-induced metabolic side effects in schizophrenia?
Vasileva, S. S., Tucker, J., Siskind, D. J., & Eyles, D. W. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2042251 · Cited by 21
“Morgan et al. (2014) conducted a similar experiment but used germ-free mice.”
BackgroundMethodChang, X., Shen, Y., Yang, M., Yun, L., Liu, Z., Feng, S., Yang, G., Meng, X., & Su, X. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.134444 · Cited by 21
Luo, C., Wang, X., Huang, H., Mao, X., Zhou, H., & Liu, Z. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05677-8 · Cited by 19
“In conventional housing conditions, OLZ treatment increased body weight in high-fat diet-fed mice; however, OLZ-treated germ-free mice showed no significant difference in body weight (Morgan et al. 2014).”
BackgroundBall, R. L., Bogue, M. A., Liang, H., Srivastava, A., Ashbrook, D. G., Lamoureux, A., Gerring, M. W., Hatoum, A. S., Kim, M. J., He, H., et al. (2024) · Genome Research · doi:10.1101/gr.278157.123 · Cited by 23
“…et al. 2005; Jackson Laboratory 2006; Svenson et al. 2007; Champy et al. 2008; Li et al. 2008; Center for Genome Dynamics 2009; Shockley et al. 2009; Philip et al. 2011; Tsuchiya et al. 2012; Ghazalpour et al. 2014; Morgan et al. 2014; Keller et al. 2018; Kollmus et al. 2020; Bachmann et al. 2022).”
Chen, H., Cao, T., Zhang, B., & Cai, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1097284 · Cited by 18
“Given that SGA-induced lipid disturbances are frequently associated with an increased ratio of Firmicutes to Bacteroidetes, this finding raises the possibility that women are more susceptible than men to abnormal lipid metabolism (Morgan et al., 2014).”
BackgroundResultInfluentialCampanale, A., Inserra, A., & Comai, S. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111058 · Cited by 20
“These GM alterations are at least partially due to the antimicrobial effects of olanzapine, which can inhibit completely the growth of certain bacterial species (Morgan et al., 2014) and may exacerbate the likelihood of developed comorbid GI and metabolic comorbidities.”
BackgroundInfluentialThe Obesity–Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients
Sfera, A., Osorio, C. P., Inderias, L., Parker, V., Price, A. I., & Cummings, M. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00020 · Cited by 20
“Interestingly, fecal analysis of olanzapine treated rodents, demonstrated increases in Firmicutes and decreases in Bacteriodetes phyla, a pattern identical to the one found in obese humans (165, 166).”
ResultMichaelis, L., Berg, L., & Maier, L. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.06.004 · Cited by 22
Wu, H., Jiawei, X., Wen, Z., Han, Y., Liu, Y., Chen, S., Ye, Z., Li, J., Xie, L., & Wu, X. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf028 · Cited by 17
Susceptibility of male wild type mouse strains to antipsychotic-induced weight gain
Zapata, R. C., & Osborn, O. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.112859 · Cited by 16
The gut microbiota as a biomarker for realistic exposures to pesticides: A critical consideration
Gambarte, P. K., & Wolansky, M. J. (2022) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2022.107074 · Cited by 15
Zapata, R. C., Silver, A., Yoon, D., Chaudry, B. S., Libster, A. M., McCarthy, M. J., & Osborn, O. (2022) · Schizophrenia · doi:10.1038/s41537-022-00276-2 · Cited by 17
Mötteli, S., Vetter, S., Colla, M., & Hotzy, F. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02735-z · Cited by 15
“This might be one reason that treatment with psychiatric medication is associated with a less diverse microbiome composition [14, 15], which, again, is associated with weight gain [28, 29].”
BackgroundSuh, S. B., Lee, N., Kim, J., Kim, S., Jang, S., Park, J. K., Lee, K., Choi, S. Y., Kwon, H., & Lee, C. H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.906717 · Cited by 14
“Administering OLZ to mice in conjunction with a 45% HFD is a widely used method because this mode of drug administration closely resembles that of humans (Morgan et al., 2014; Perez-Gomez et al., 2018; Zapata et al., 2020).”
MethodLiu, Y., Wu, H., Liu, B., Chen, S., Huang, L., Liu, Z., Wang, J., Xie, L., & Wu, X. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.06.040 · Cited by 17
Microbiome-driven precision medicine: advancing drug development with pharmacomicrobiomics
Ebadpour, N., Abavisani, M., & Sahebkar, A. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2509283 · Cited by 18
“…may mitigate these effects, indicating a direct correlation between microbiota composition and olanzapine-induced metabolic dysfunction [19–21]. in contrast to olanzapine, lurasidone does not substantially affect the gut microbiome or induce metabolic disorders. it may positively…”
Nuclear receptor 5A2 regulation of Agrp underlies olanzapine-induced hyperphagia
Zapata, R. C., Zhang, D., Libster, A. M., Porcu, A., Montilla‐Perez, P., Nur, A., Xu, B., Zhang, Z., Correa, S. M., Liu, C., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01981-9 · Cited by 12
“Sample sizes were based on previous similar studies [28, 29, 65, 66].”
MethodResultTadmor, H., Golani, I., Doron, R., Kremer, I., & Shamir, A. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.08.010 · Cited by 14
Ferreira, V., Folgueira, C., García‐Altares, M., Guillén, M., Ruíz-Rosario, M., Nunzio, G. D., García‐Martinez, I., Alén, R., Bookmeyer, C., Jones, J. G., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102741 · Cited by 15
“OLA treatment by oral gavage: mice received a daily (10 – 12 a.m.) oral gavage of OLA at 10 mg/kg, dose previously reported for oral treatment by our group and others [32,37,39,45 – 48], or VEH (4% v/v DMSO in 0.9% NaCl) for 8 weeks.”
InfluentialFerrari, S., Mulè, S., Rosso, G., Parini, F., Galla, R., Molinari, C. G., & Uberti, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094774 · Cited by 15
“Thus, it was postulated that olanzapine affects AIWG via in vitro antibacterial action against resident intestinal bacteria [25].”
BackgroundBui, T. A., O’Croinin, B. R., Dennett, L., Winship, I. R., & Greenshaw, A. J. (2025) · Microbiology · doi:10.1099/mic.0.001568 · Cited by 16
“Specifically, olanzapine increased the abundance of Erysipelotrichia (phylum Firmicutes ) and Gammaproteobacteria (phylum Proteobacteria ), while decreasing Bacteroidia (phylum Bacteroidetes ) [89].”
InfluentialThe Other Obesity Epidemic—Of Drugs and Bugs
Sfera, A., Osorio, C. P., Diaz, E. L., Maguire, G. A., & Cummings, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00488 · Cited by 13
“Long-term exposure to these atypical antipsychotics (AAPs) increases the risk of metabolic adverse effects and weight gain (1, 2).”
BackgroundInfluentialAmdanee, N., Shao, M., Hu, X., Fang, X., Zhou, C., Chen, J., Chattun, M. R., Wen, L., Pan, X., Zhang, X., et al. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac202 · Cited by 13
Factors influencing gut microbial colonization: A host-microbe-environment interaction perspective
Zhao, Y., Ren, Z., Xu, Q., Zhu, T., Hu, H., Fu, Y., Jiang, J., & Zhai, Q. (2026) · Current Research in Food Science · doi:10.1016/j.crfs.2026.101361 · Cited by 17
“…taxa (e.g., Clostridium , Enterobacteriaceae ) and shifts communities toward an obesogenic profile, whereas antidepressants such as venlafaxine perturb microbial tryptophan pathways, reducing neuromodulatory metabolites (e.g., indolepropionate) (Cussotto et al., 2019; Morgan et al., 2014).”
Wake, D. J., Broughton, P., Perera, S. M., MacIntyre, D. J., & Leese, G. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.01.022 · Cited by 9
“Emerging evidence suggests that antipsychotic medication may alter gut microbiota which may precipitate weight gain and predispose patients to diabetes (Bahr et al., 2015; Morgan et al., 2015).”
The Microbiome Factor in Drug Discovery and Development
Nuzzo, A., & Brown, J. R. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00333 · Cited by 11
Li, S., Fu, Y., Wang, W., Qiu, J., Huang, Y., Li, X., Yang, K., Yu, X., Ma, Y., Zhang, Y., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240815120547 · Cited by 10
“Notably, in contrast to previous studies [49-51], OLA did not increase weight in different rodent models in our study.”
Zapata, R. C., Rosenthal, S. B., Fisch, K. M., Dao, K., Jain, M., & Osborn, O. (2020) · Scientific Reports · doi:10.1038/s41598-020-75624-2 · Cited by 12
Rotem‐Kohavi, N., Keane, J., Clarke, G. A., Dinan, T. G., Cryan, J. F., McCarthy, F. P., Oberlander, T. F., & O’Mahony, S. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-60159-1_8 · Cited by 9
Metformin acts on the gut-brain axis to ameliorate antipsychotic-induced metabolic dysfunction
Wang, X., Huang, H., Zhu, Y., Li, S., Zhang, P., Jiang, J., Xi, C., Wu, L., Gao, X., Fu, Y., et al. (2021) · BioScience Trends · doi:10.5582/bst.2021.01317 · Cited by 11
“Pre-clinic studies have found that traditional mice treated with OLZ and high-fat diet had more significant weight gain than those treated with high-fat diet only, but no significant difference was found in the same treatment of sterile mice ( 22 ).”
InfluentialMicrobiome: The Missing Link in Neuropsychiatric Disorders
Evrensel, A., & Ceylan, M. E. (2017) · EMJ Innovation · doi:10.33590/emjinnov/10313424 · Cited by 10
Rampino, A., Torretta, S., Gelao, B., Veneziani, F., Iacoviello, M., Marakhovskaia, A., Masellis, R., Andriola, I., Sportelli, L., Pergola, G., et al. (2021) · European Psychiatry · doi:10.1192/j.eurpsy.2021.26 · Cited by 8
Abolghasemi, A., Manca, C., Iannotti, F. A., Shen, M., Leblanc, N., Lacroix, S., Martin, C., Flamand, N., Marzo, V. D., & Silvestri, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212361 · Cited by 8
“A study in rats suggested that changes in the fecal microbiota profile of olanzapine-treated rats might be related to the dysmetabolic effects of this drug [6], while germ-free mice are largely resistant to olanzapine-mediated weight gain, which is reversed when gut microbiota have been reintroduced [7].”
Yeo, J. (2023) · Food Science and Biotechnology · doi:10.1007/s10068-023-01293-2 · Cited by 9
The 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile
Boustany, A., Feuerstadt, P., & Tillotson, G. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02972-0 · Cited by 9
“Olanzapine, interestingly, inhibited E. coli and Enterococcus faecalis in vitro at supraphysiologic concentrations but did not affect the gut microbiome in a rodent model [66].”
BackgroundConserved immunomodulatory transcriptional networks underlie antipsychotic-induced weight gain
Zapata, R. C., Chaudry, B. S., Valencia, M. L., Zhang, D., Ochsner, S. A., McKenna, N. J., & Osborn, O. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01528-y · Cited by 7
“In addition, olanzapine was dosed in the diet (54 mg/kg diet) resulting in mouse plasma levels (21 ± 5 ng/mL) that are similar to the levels observed in humans treated with olanzapine (10–50 ng/mL) [17].”
BackgroundResultInfluentialSeguin, I., Medak, K. D., Shamshoum, H., Hahn, M., & Wright, D. C. (2023) · Obesity · doi:10.1002/oby.23630 · Cited by 6
“This mode of OLZ treatment has been previously shown to cause weight gain in female C57BL6/J mice and result in increases in circulating OLZ concentrations similar to what is seen clinically [15].”
MethodImpact of clozapine monotherapy on gut microbiota and metabolism in people with schizophrenia
Yin, F., Shi, Z., Ma, X., Ding, K., Zhang, Y., & Ma, S. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1253156 · Cited by 7
“Olanzapine has contributed to a shift in gut microbiota toward an “obesogenic” bacterial profile (Morgan et al., 2014); increased the abundance of Short Chain Fatty Acids (SCFA) producing gut microbiota increased the levels of SCFAs, which are strongly associated with the development of lipid…”
BackgroundHisamatsu, D., Masuoka, H., Takeshige‐Amano, H., Kurokawa, R., Ogata, Y., Suda, W., Hatano, T., Asaoka, D., Mabuchi, Y., Naraoka, Y., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112593 · Cited by 6
McDonagh, F., Murray, E. K., Hallahan, B. P., & Miliotis, G. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.05.046 · Cited by 7
Zheng, M., Yan, H., Hao, W., An, H., Chen, X., Wu, Q., Ge, X., Ye, H., Zhou, M., Zhou, G., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.03.020 · Cited by 7
Chen, H., Cao, T., Lin, C., Jiao, S., He, Y., Zhu, Z., Guo, Q., Wu, R., Cai, H., & Zhang, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1550015 · Cited by 7
Sex Differences in Fish Oil and Olanzapine Effects on Gut Microbiota in Diet-Induced Obese Mice
Abbas, M. M., Soto, P. L., Ramalingam, L., EL‐Manzalawy, Y., Bensmail, H., & Moustaïd‐Moussa, N. (2022) · Nutrients · doi:10.3390/nu14020349 · Cited by 6
“Although OLZ failed to increase body weight in female mice, it slightly reduced body weight in male mice; the results provide an opportunity to compare changes in gut microbiota in OLZ- and HF-treated mice to compare toa previous results indicating that treatment with OLZ shifts gut bacteria toward an obesogenic profi…”
BackgroundResultSimon, M. S., Barton, B. B., Glocker, C., & Musil, R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271793 · Cited by 5
Hubeňák, J., Mžik, M., Laštůvková, H., Bayer, D., Jandová, L., Schreiberová, J., Andrýs, C., Mičuda, S., Masopust, J., & Chládek, J. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf036 · Cited by 5
Soto, P. L., Ramalingam, L., George, B. E., & Moustaïd‐Moussa, N. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06193-7 · Cited by 4
Zapata, R. C., Zhang, D., Yoon, D., Nasamran, C. A., Chilin-Fuentes, D., Libster, A. M., Chaudry, B. S., Valencia, M. L., Ponnalagu, D., Singh, H., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101794 · Cited by 5
Shamshoum, H., Medak, K. D., McKie, G. L., Jeromson, S., Hahn, M., & Wright, D. C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115671 · Cited by 4
Gut Microbiota and Antipsychotics Induced Metabolic Alteration
Kan, D.-Y., Li, S., Liu, C., & Wu, R. (2019) · Global Clinical and Translational Research · doi:10.36316/gcatr.01.0020 · Cited by 6
Ball, R. L., Bogue, M. A., Liang, H., Srivastava, A., Ashbrook, D. G., Lamoureux, A., Gerring, M. W., Hatoum, A. S., Kim, M. J., He, H., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.08.552506 · Cited by 5
Wu, Y., Zang, S., Wu, Z., & Huang, J. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1722760 · Cited by 3
Ye, H., Yang, X., Zheng, M., Dong, W., Chen, X., Chen, J., Hu, M., Zhou, M., Zheng, P., Shen, L., et al. (2026) · Microbiome · doi:10.1186/s40168-026-02358-0 · Cited by 5
“Notably, heightened levels of p-cresol have been detected in children with autism, a condition that is associated with the neurotoxic properties of p-cresol [51–53], which instigate endoplasmic reticulum stress, ultimately leading to neurological dysfunction [19, 43, 44].”
Tufvesson‐Alm, M., Walsh, L., Pierce, S., Keohane, F., Clarke, G. A., O’Connor, K. M., Cryan, J. F., & Schellekens, H. (2026) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2026.2637716 · Cited by 5
“…gain. this finding was further expanded on in subsequent studies, showing that germ-free mice do not exhibit antipsychotic-induced weight gain (Morgan et al. 2014) and that faecal microbiota transfer from RiS-treated mice to controls induced changes in metabolism similar to RiS (Bahr et al.…”
InfluentialZeng, C., Chen, H., Cao, T., Wang, L., Jiao, S., Lin, C., Zhang, B., & Cai, H. (2024) · Food and Chemical Toxicology · doi:10.1016/j.fct.2024.114490 · Cited by 3
A Possible Role of Akkermansia muciniphila in the Treatment of Olanzapine-Induced Weight Gain
Bertossi, F. (2024) · Cureus · doi:10.7759/cureus.55733 · Cited by 5
“The concentration of A. muciniphila is reduced in patients with bipolar disorder treated with SGAs [44] and in mice administered with olanzapine [45], modifications of gut microbiota with olanzapine have also been demonstrated to have been altered in other studies [46,47].”
BackgroundResultBachtarzi, R., Boureau, A., Mascart, C., Batard, É., Montassier, E., Bémer, P., Bourigault, C., Berrut, G., de Decker, L., & Chapelet, G. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s200029 · Cited by 3
Functional coupling between MC4R and Kir7.1 contributes to clozapine-induced hyperphagiaPreprint
Li, L., Hernández, C. C., Gimenez, L. E., Xu, B., Dahir, N. S., SWATI, S., Birnbaum, S. G., Cone, R. D., & Liu, C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.07.597973 · Cited by 3
Perrotta, C., Carnovale, C., Pozzi, M., Palma, C. D., Cervia, D., Nobile, M., & Clementi, E. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100061 · Cited by 4
Kancsev, A., Engh, M. A., Horváth, A., Hegyi, P., Kelemen, O., & Kéri, S. (2025) · Schizophrenia · doi:10.1038/s41537-025-00694-y · Cited by 3
“…medications used in the treatment of SCZ can induce metabolic side effects through various mechanisms, such as alterations in the gut microbiome, impaired central glucose sensing in the hypothalamus, weight gain, and dysregulation of peripheral glucose and lipid metabolism 15,62 – 64 .”
Dhieb, D., & Bastaki, K. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1778794 · Cited by 2
“In germ-free mice, olanzapine-associated weight gain is absent but can be induced following colonization with gut microbes (68).”
Huang, L., Sun, Y., Luo, C., Wang, W., Shi, S., Sun, G., Ju, P., & Chen, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1419098 · Cited by 3
Lozano, A. F. Q., Guimarães, I. C., González, L. N., Cuasnicu, P. S., Cohen, D. J., & Kempinas, W. D. G. (2024) · Reproductive Toxicology · doi:10.1016/j.reprotox.2024.108755 · Cited by 4
Evrensel, A., & Ceylan, M. E. (2015) · Cited by 2
Liu, Y., Wu, H., Liu, B., Chen, S., Huang, L., Liu, Z., Wang, J., Xie, L., & Wu, X. (2022) · Research Square · doi:10.21203/rs.3.rs-2346866/v1 · Cited by 2
Kamath, S., Hunter, A., Collins, K., Wignall, A. D., & Joyce, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.28.582623 · Cited by 2
Singh, R., Pereira, S., Panganiban, K. J., Hamel, L., Wright, D. C., Prevot, T. D., Müller, D. J., Remington, G. J., Agarwal, S. M., Berčík, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.13.675957 · Cited by 2
“Indeed, colonization of germ-free mice and another seven-week treatment with OLA+HFD induced significant weight gain [32].”
InfluentialThe role of microbiome in gut-brain-axis dysbiosis causing depression: From mechanisms to treatment
Mi, J., Morys, J., Nowacka-Chmielewska, M. M., & Burek, M. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.03.006 · Cited by 1
Salama, A., Darwish, A. B., El-Shenawy, S. M. A., & Wagdi, M. A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126204 · Cited by 1
Olivares, D. V. F., Halverson, T., & Alagiakrishnan, K. (2026) · Future Pharmacology · doi:10.3390/futurepharmacol6020030 · Cited by 2
“Conversely, when the germ-free mice were colonized, this weight gain returned [20].”
Medication and Health Risks Associated With Neglected Side Effects on Gut Microbiota
Velikova, T. V., Nakov, R., & Ianiro, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00074-7 · Cited by 1
Innate Immune Response and Psychotic Disorders
Suvisaari, J., & Mantere, O. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801968-9.00007-6
Schizophrenia and intestinal microbiome
Látalová, K. (2021) · Psychiatrie pro praxi · doi:10.36290/psy.2021.002
Faculty Opinions recommendation of Extensive impact of non-antibiotic drugs on human gut bacteria.
Owens, M. J. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732860038.793582842
Skin-Gut-Breast Microbiota Axes
Drago, L. (2021) · MDPI eBooks · doi:10.3390/books978-3-0365-0899-3
Ashraf, A. H. M. Z., Pantho, A. F., Kamal, S., Caba, A., Afroze, S. H., Kuehl, T. J., Hossain, L., & Uddin, M. N. (2023) · Research Square · doi:10.21203/rs.3.rs-3050737/v1
Effect of environment of the respiratory tract on nanomedicine drug delivery
Imran, M., Chaudhary, A., Ali, M., Jha, S. K., & Mohammed, Y. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22374-7.00003-7
Yuan, H. S., Wang, M.-Y., Liu, R., Sreekissoon, S., Liu, Q., Tan, L., Zhao, Y., Zhong, M., Zhang, Q., Su, X.-L., et al. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1673931 · Cited by 1
“Previous studies have shown that olanzapine has direct antibacterial effects on Enterococcus in the intestinal tract (Morgan et al., 2014).”
Milano, W., Campanile, R., Marchese, M., Milano, M. F., Ragozino, L., Saetta, B., & Capasso, A. (2026) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2602330
Wu, H., Han, Y., Wen, Z., Liu, W., Tu, N., Yang, W., Li, J., & Zha, Y. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbag039
Zhou, Y., Yi, W., Li, F., Lan, Z., Yan, F., Tang, Y., Lu, Y., & Fang, K. (2026) · Algal Research · doi:10.1016/j.algal.2026.104855
Luo, C., Qing, G., Zhang, J., Wan, H., Xiong, S., Zhou, Y., Yan, K., & Xiong, Y. (2026) · The International Journal of Psychiatry in Medicine · doi:10.1177/00912174261474760
Gacasan, C. A., Weinberg, J., Lipson, L. D., Webster, G. M., Jones, D. P., Sampson, T. R., Jones, R. M., & Woodworth, M. H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.15.745804
Papacocea, R.-I., Gabriela, M. A., Radu-Ștefan, V., Russomano, T., & Papacocea, I. R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198471
“Germ-free and colonization experiments indicate that the presence and composition of an intestinal microbial community contribute to olanzapine-associated weight gain [17].”
InfluentialNanoparticles and the gut-microbiome: a dual strategy for oral brain delivery
Negahdari, R., Pouyanfar, N., Masoudifar, R., Aftabi, P., Fendereski, F., Anvari, Z., Masoumi, N., Faizi, M., & Ghorbani‐Bidkorbeh, F. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127477
Stepensky, D. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101276
“…evidence: germ-free mice are almost entirely protected from olanzapine-induced weight gain, and the metabolic phenotype is partially transmissible via fecal microbiota transplantation (FMT) from olanzapine-treated to untreated animals (Level 3, strong causal evidence within the animal model) [57].”
Ahmed, L. A., & Al‐Massri, K. F. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06192-1
Metadata
- Authors
- Morgan, A. P., Crowley, J. J., Nonneman, R. J., Quackenbush, C. R., Miller, C. N., Ryan, A. K., Bogue, M. A., Paredes, S. H., Yourstone, S., Carroll, I. M., Kawula, T. H., Bower, M. A., Sartor, R. B., & Sullivan, P. F.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Jackson Laboratory (US)
- Corresponding author
- Sullivan, Patrick F.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-12-15
- Volume
- 9
- Issue
- 12
- Pages
- e115225
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4266663
- OpenAlex
- W2072944905
- Cited by
- 197
- References
- 61
- Citations by year
- 2026: 16 · 2025: 16 · 2024: 19 · 2023: 25 · 2022: 21 · 2021: 17 · 2020: 22 · 2019: 23 · 2018: 16 · 2017: 9 · 2016: 7 · 2015: 6
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- UNC Libraries
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (P40OD010995)
- National Institute of Mental Health (R21MH097173, K01MH094406, F30MH103925)
- National Institute of General Medical Sciences (T32GM008719, T32GM067553)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034987, P30DK056350)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- olanzapine, gut microbiota, weight gain, antipsychotic adverse effects, germ-free mice, antimicrobial activity, atypical antipsychotics, drug-microbiome interactions
- MeSH terms
- Gastrointestinal Microbiome, Olanzapine, Animals, Benzodiazepines, Female, Antipsychotic Agents, Weight Gain, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.